Immunohistochemical Expression of TRIP13 in Transitional and Squamous cell carcinoma of Urinary Bladder Carcinoma | ||
| Minia Journal of Medical Research | ||
| Articles in Press, Accepted Manuscript, Available Online from 20 February 2023 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mjmr.2023.189765.1317 | ||
| Authors | ||
| arwa Ibrahim Mohammed* ; Maram El-Hussieny Ali; Fatma Elzahraa Ammar Mohamed; Dalia Mohamed Abd-Elrehim | ||
| Department of pathology, Faculty of Medicine, Minia University, Egypt | ||
| Abstract | ||
| Background: Urinary bladder carcinoma (UBC) is the 9th most common cancer globally. Thyroid receptor-interacting protein 13 (TRIP13) is a member of the AAA+ ATPase family. The upregulation of TRIP13 has been shown to be involved in the development and progression of different tumors, including UBC. Method: The current study included 50 formalin-fixed, paraffin-embedded tissue specimens of UBC. Tissue sections have been subjected to haematoxylin and eosin staining and immunohistochemical staining for TRIP13 expression. TRIP13 expression was estimated and its associations with clinicopathological factors were evaluated. The prognostic significance of TRIP13 was evaluated using univariate and multivariate COX regression analyses. Results: In the present study, 62% (n=31) of the cases showed ‘negative/low’ TRIP13 expression, whereas 38% (n=19) showed ‘high’ TRIP13 expression. A significant association was found between TRIP13 expression and tumor grade, stage, lymph node metastasis (LNM) and distant metastasis (P=0.012, 0.007, 0.045, <0.001, and 0.004 respectively). In addition, TRIP13 was remarkably correlated with poor prognosis. Conclusion: TRIP13 plays a key role in UBC progression and spread. Our finding also suggests TRIP13 as a novel and prognostic marker in UBC. | ||
| Keywords | ||
| Key Words: Immunohistochemistry; TRIP13; Urinary bladder carcinoma | ||
|
Statistics Article View: 155 |
||
